Response to the letter from Dr. Veerman and colleagues

Psychopharmacology (Berl). 2017 Dec;234(23-24):3537-3538. doi: 10.1007/s00213-017-4757-8. Epub 2017 Oct 7.

Taro Kishi¹, Toshikazu Ikuta², Yuki Matsuda^{3

4}, Nakao Iwata³

¹ Department of Psychiatry, Department of Psychiatry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. tarok@fujita-hu.ac.jp.
² Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, University, MS, 38677, USA.
³ Department of Psychiatry, Department of Psychiatry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
⁴ Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8551, Japan.

No abstract available

Publication types